RheumaGen

RheumaGen is a pioneering, private biotech based in San Diego developing potentially curative HLA gene-editing therapies for autoimmune diseases. The company's platform targets the root genetic cause of autoimmunity, with an initial focus on refractory rheumatoid arthritis, progressive multiple sclerosis, type 1 diabetes, and ankylosing spondylitis. Led by a co-founding team with deep expertise in immunology, business, and law, RheumaGen is in the pre-clinical stage and is backed by strategic investors like Beyond Celiac Investments. Its ambitious vision is to transform autoimmunity from a chronic, managed condition into a curable one.

Proprietary platform for editing the Human Leukocyte Antigen (HLA) genes, the fundamental 'immune genes' associated with autoimmune disease susceptibility. The approach involves ex vivo gene editing of a patient's own cells to modify disease-linked HLA variants, aiming to create a one-time, curative cell therapy that prevents the immune system from attacking healthy tissue.

RheumaGen's approach is highly novel, with few direct competitors targeting HLA editing for autoimmunity. However, it competes indirectly with developers of next-gen biologics, immune modulators, and other cell/gene therapy approaches (e.g., CAR-Tregs). Its main competition is the entrenched standard of care—effective but non-curative and chronic biologic therapies.